To Top

Content Filter


1631 Articles available
Collaboration

GeneNews Announces Collaboration with AIM Laboratories to Expand Test Utilization

PR-M05-18-NI-078
Phase 3 Trial

LYRICA® (pregabalin) Oral Solution CV Phase 3 Trial in Pediatric Epilepsy Meets Primary Endpoint

PR-M05-18-NI-077
Clinical Data

Regeneron and Sanofi Share First Positive Clinical Data for Cemiplimab in Advanced Non-small Cell Lung Cancer at ASCO

PR-M05-18-NI-075
FDA Approval

FDA approves the first non-opioid treatment for management of opioid withdrawal symptoms in adults

PR-M05-18-NI-079
Immunotherapy

Cancer Immunotherapies Reach Patients More Quickly Than Other Drugs

PAO-M05-18-NI-013
Diagnostics

Researchers Develop Diagnostic for Rare Cancer-Generated Glycoproteins

PAO-M05-18-NI-012
Cell and Gene Therapy

Bioverativ and Sangamo Announce FDA Acceptance of IND Application for Gene-Edited Cell Therapy BIVV003 to Treat Sickle Cell Disease

PR-M05-18-NI-074
Biologics

WuXi Biologics to Build an Integrated Biologics Development, Clinical and Commercial Manufacturing Center in Shijiazhuang

PR-M05-18-NI-070
FDA Approval

U.S. Food and Drug Administration Approves Expanded Indication for Truvada®

PR-M05-18-NI-073
Positive Trial

Positive Phase 3 Trial of DUPIXENT® (dupilumab) in Adolescents with Inadequately Controlled Moderate-to-severe Atopic Dermatitis

PR-M05-18-NI-072
FDA Approval

Pfizer’s Biosimilar RETACRIT® (epoetin alfa-epbx) Approved by U.S. FDA

PR-M05-18-NI-071
Cell and Gene Therapy

Editas Founders Start New Gene Editing Company

PAO-M05-18-NI-011
Immunotherapy

Medigene, Bluebird Bio Collaboration on TCR Immunotherapy Extended

PAO-M05-18-NI-010
Used Equipment

With Expertise Comes Security

PA-M05-18-CL-001
Clinical Data

X4 Pharmaceuticals Presents Clinical Data Demonstrating Combinability of X4P-001-IO and Opdivo® (nivolumab) in Patients with Clear Cell Renal Cell Carcinoma

PR-M05-18-NI-068
Clinical Trial

Research Ready™ Program Expands and Diversifies Clinical Trial Patient Populations

PR-M05-18-NI-065
Collaboration

Kite Announces New Worldwide Facilities and Expanded Collaboration With National Cancer Institute to Support Cell Therapy Pipeline

PR-M05-18-NI-066
Acquisition

Lilly to Acquire AurKa Pharma

PR-M05-18-NI-065
Zika Test

FDA approves additional claim for Roche cobas Zika test

PR-M05-18-NI-061
Drug Development

Novartis announces FDA approval of Gilenya® as the first disease-modifying therapy for pediatric relapsing multiple sclerosis

PR-M05-18-NI-060
FDA Approval

Grifols Expands its Blood Typing Solutions Portfolio in the United States with Antisera Reagents

PR-M05-18-NI-058
FDA Clearance

Baxter Announces U.S. FDA Clearance of New Spectrum IQ Infusion System

PR-M05-18-NI-059
Capacity Expansion

Marken Announces Expansion Of Cryogenic Services

PR-M05-18-NI-069
Oncology

Roche’s TECENTRIQ (Atezolizumab) Receives Priority Review

PAO-M05-18-NI-009
Acquisition

Eli Lilly Makes Two Acquisitions in the Oncology Space

PAO-M05-18-NI-008
FDA Clearance

Faxitron VisionCT System Granted 510(k) Clearance for True 3D Imaging of Breast Specimens

PR-M05-18-NI-057
Preclinical Data

Recently Presented Preclinical Data Show Potential for ADXS-NEO as Anti-Cancer Immunotherapy Agent

PR-M05-18-NI-056
Oncology

Cancer Treatment Developed at Ben-Gurion University Shows Ability to Reprogram Cancer Cells to Pre-Cancerous State

PR-M05-18-NI-054
Supply Agreement

AGC Biologics Enters into Commercial Supply Agreement with MacroGenics

PR-M05-18-NI-053
Partnership

Philips, Emory Healthcare and Royal Perth Hospital in Australia partner to launch remote intensive care monitoring program

PR-M05-18-NI-055
Preclinical Results

NeuClone Announces Preclinical Results for Stelara® (ustekinumab) Biosimilar Candidate

PR-M05-18-NI-052
Collaboration

FORMA Therapeutics and the University of Oxford Announce Multi-Year Collaboration to Advance the Development of Deubiquitinating Enzyme (DUB) Inhibitors

PR-M05-18-NI-051
Collaboration Agreement

Polaris Signs Collaboration Agreement with MD Anderson Cancer Center to Join its Immunotherapy Platform for Clinical Trials and Preclinical Research

PR-M05-18-NI-050
Acquisition

Lilly Announces Agreement To Acquire ARMO BioSciences

PR-M05-18-NI-049
Clinical Trials

Genentech Provides Update on Phase III Study of TECENTRIQ (Atezolizumab) and COTELLIC (Cobimetinib)

PR-M05-18-NI-048
Innovative Drugs

Innovative Drugs and Anti-Cancer Compounds Are Most Welcome in the Chinese Market, Says Asia-Pacific CRO George Clinical

PR-M05-18-NI-058
Strategic Collaboration

Evotec and Carna Biosciences Collaborate on Indigo Platform

PR-M05-18-NI-047
Manufacturing Agreement

Proteon Therapeutics and Lonza Extend Manufacturing Agreement for Commercial Supply

PR-M05-18-NI-046
FDA Inspection

Cytovance® Biologics Successfully Completes FDA Inspection

PR-M05-18-NI-044
Strategic Partnership

EA Health and Photon Announce Strategic Partnership

PR-M05-18-NI-043
Licensing Agreement

DURECT Announces Amendment to Licensing Agreement with Sandoz Related to POSIMIR® (SABER®-Bupivacaine)

PR-M05-18-NI-042
Biosimilars

GlobalData Predicts Strong Sales for Humira Biosimilars in Europe

PAO-M05-18-NI-006
Acquisition

Takeda Acquires Shire for $62 Billion

PAO-M05-18-NI-005
FDA

New WuXi STA Solid-Dose API Plant Gets Okay from US FDA

PAO-M05-18-NI-004
Drug Discovery

XtalPi Inc. Announces Strategic Research Collaboration with Pfizer Inc. to Develop Artificial Intelligence-Powered Molecular Modeling Technology for Drug Discovery

PR-M05-18-NI-041
Endpoint

Phase III Study Evaluating the Efficacy and Safety of Lonsurf in Patients with Metastatic Gastric Cancer Meets Primary Endpoint

PR-M05-18-NI-040
Clinical Research

Worldwide Clinical Trials and Datavant Take Steps Toward Transforming Clinical Trial Success in Neurodegenerative Diseases

PR-M05-18-NI-039
Discovery Platform

Biomax Informatics Software Licensed by Global Pharma Company, Boehringer Ingelheim, to Build a Target Discovery Knowledge Platform

PR-M05-18-NI-038
Announcement

Alcami St. Louis Facility to be Honored by Missouri House of Representatives and City of St. Louis

PR-M05-18-NI-032
Research

Alkermes Launches Award Program To Support And Advance Central Nervous System Disorders Research

PR-M05-18-NI-033
Drug Development

Praxbind®, Specific Reversal Agent for Pradaxa®, Now Available in 3,200 Hospitals Nationwide

PR-M05-18-NI-034
IPO

WuXi AppTec Announces Listing of Initial Public Offering of Common Stock on Shanghai Stock Exchange

PR-M05-18-NI-037
Announcement

Sanofi Named to DiversityInc's Top 50 Companies for Diversity®

PR-M05-18-NI-031
Extended Relationship

Charles River Laboratories Announces Extended Relationship with The Michael J. Fox Foundation

PR-M05-18-NI-030
Data Presentation

Janssen to Present Data in Treatment-Resistant Mental Ilnesses

PR-M05-18-NI-029
Investment

Novasep Invests €10M in "SeneFill," Its New Facility for Commercial Aseptic Fill & Finish Operations

PR-M05-18-NI-028
Prescribing Information

TRINTELLIX® Prescribing Information Now Includes New Data Showing Improvement in Processing Speed

PR-M05-18-NI-027
Clinical Trials

Merck Provides Update on KEYNOTE-407 Trial

PR-M05-18-NI-026
Acquisition

Janssen to Acquire BeneVir Biopharm to Advance Immunotherapy Regimens

PR-M05-18-NI-021
FDA Approval

Bausch + Lomb ULTRA® Contact Lenses Receive FDA Approval for Extended Wear Indication

PR-M05-18-NI-022
Expansion

Evotec Expands CRISPR-Based Technology Offering with Licence from ERS Genomics

PR-M05-18-NI-023
Drug Discovery

Bactevo Enters Drug Discovery Agreement with Boehringer Ingelheim

PR-M05-18-NI-024
Collaboration

Baxter and the International Society of Nephrology Announce a Collaboration to Address Growing Prevalence of Kidney Disease

PR-M05-18-NI-025
Commercial Manufacturing Agreement

AGC Biologics Enters into Commercial Manufacturing Agreement with Horizon Pharma plc

PR-M05-18-NI-036
Clinical Data

Study Shows AST-005 is Safe and Tolerable in Patients at Higher Doses than Previously Studied

PAO-M05-18-NI-003
Inflammatory Disease

Gilead Sciences and Verily Life Sciences LLC Enter Collaboration, Hope to Better Understand Inflammatory Diseases

PAO-M05-18-NI-002
Strategic Partnership

Roche Expands Partnership with 4D Molecular Therapeutics to Treat Night Blindness

PAO-M05-18-NI-001
Authorization Application

AbbVie Submits Marketing Authorization Application to the European Medicines Agency for Investigational Treatment Risankizumab for Moderate to Severe Plaque Psoriasis

PR-M05-18-NI-016
Partnership

Spectrum Pharmaceuticals Enters into a Next-Generation Sequencing Companion Diagnostic Partnership with Thermo Fisher Scientific

PR-M05-18-NI-017
Collaboration

LabCorp Announces Collaboration with The Recovery Platform to Assist Physicians Treating Patients with Opioid Dependency

PR-M05-18-NI-018
Clinical Data

New Study Finds Probiotic Treatment Can Reduce Rehospitalization for Individuals with Mania

PR-M05-18-NI-019
Investment

WuXi Biologics to Invest €325 Million to Build Largest Biomanufacturing Facility Using Single-Use Bioreactors in Ireland

PR-M05-18-NI-011
Distribution Agreement

RenalSense Announces Distribution Agreement With Fresenius Medical Care

PR-M05-18-NI-012
Partnership

4DMT and ROCHE Expand Ophthalmology Partnership to Develop and Commercialize Multiple AAV Gene Therapy Products

PR-M05-18-NI-014
Research

Sancilio Pharmaceuticals Company to Present New Research on Altemia™ to Treat Sickle Cell Disease at the ASPHO Conference

PR-M05-18-NI-015
Strategic Collaboration

Thermo Fisher and Leica Collaborate to Develop Integrated Cryotomography Workflow Solution

PR-M05-18-NI-009
Clinical Data

Teva Presents New Long-Term Data Demonstrating Efficacy and Safety of COPAXONE® (glatiramer acetate injection) 40 mg/mL

PR-M05-18-NI-013
Clinical Trials

Alkermes Completes Patient Enrollment in Pivotal Weight Study of ALKS 3831 for Schizophrenia

PR-M05-18-NI-007
Collaboration

InSysBio, LLC Announces Extension of Collaboration With GSK on Quantitative Systems Pharmacology Modeling in Asthma

PR-M05-18-NI-006
Expansion

Marken Announces Expanded Hybrid Services In Latin America

PR-M05-18-NI-015
Clinical Data

DiscGenics Announces First Patient Treated in U.S. Clinical Trial of IDCT for Degenerative Disc Disease

PR-M04-18-NI-004
Drug Development

BIOCAD: Interleukin-17 Inhibitor Shows High Efficacy After One Year of Therapy in Psoriasis Patients

PR-M04-18-NI-003
Expanded Capacity

WuXi STA to Build a New R&D Center in Shanghai

PR-M05-18-NI-001
Announcement

Samsung BioLogics Becomes the First in the South Korean Pharma Industry to Achieve ISO 22301 Certificate

PR-M04-18-NI-101
R&D

Boehringer Ingelheim R&D Pushes to Transcend Disease Boundaries

Acquisition

LSNE Announces Acquisition Of PSC Biotech's Parenteral Manufacturing Facility

PR-M04-18-NI-99
Radiography

Samsung Announces Commitment to Lower Dose Exposure Within its Digital Radiography Suite

PR-M04-18-NI-98
Expanded Capacity

Grand River Aseptic Manufacturing, Inc. Expands Pharmaceutical Manufacturing Capacity with Major Equipment Purchase

PR-M04-18-NI-97
Strategic Collaboration

Asembia Expands Collaboration with Pfizer Oncology

PR-M04-18-NI-95
Collaboration

Collaboration Intends to Improve Multidisciplinary Teaching and Research in Biotech

PAO-M04-18-NI-023
Survey Data

Good News for Cancer Survivors

PAO-M04-18-NI-022
Diagnostics

Development of Blood Tests for Early Cancer Detection May Be Possible

PAO-M04-18-NI-020
Preclinical Data

Encouraging Preclinical Data for Anticancer Drugs Reported by Verseon

PAO-M04-18-NI-019
Drug Candidate

STA Pharmaceutical Co. to Manufacture Phoenix Molecular Designs’ Anticancer Candidate

PAO-M04-18-NI-018
Patient Adherence

New Approach by Novo Nordisk Ties Pricing to Patient Behavior

PAO-M04-18-NI-017
Drug Supply

Innovation Pharmaceuticals Signs Drug Supply Contract with Evonik to Bulk Produce Commercial-Grade Brilacidin

PR-M04-18-NI-94
FDA

Pfizer Granted FDA Breakthrough Therapy Designation for TRUMENBA®(Meningococcal Group B Vaccine)

PR-M04-18-NI-92
FDA

FDA authorizes new use of test, first to identify the emerging pathogen Candida auris

PR-M04-18-NI-93
Awards

Cobra Biologics Receives the Queen’s Award for Enterprise in International Trade

PR-M04-18-NI-91
Biologics

Thermo Fisher Scientific Announces $50 Million Investment to Enhance Biologics Capabilities

PR-M04-18-NI-90
Strategic Collaboration

Biogen and Ionis Expand Strategic Collaboration to Develop Drug Candidates for a Broad Range of Neurological Diseases

PR-M04-18-NI-90
Expanded Capacity

Nelson Labs Significantly Expands Lab Operations and Testing Capabilities in Itasca, Illinois, to Better Serve Customer Needs

PR-M04-18-NI-89
Appointment

Xellia Pharmaceuticals Appoints Craig Boyd as President, Xellia US as it Expands its Commercial Organization

PR-M04-18-NI-87
Acquisition

P&G Acquires the Consumer Health Business of Merck KGaA, Darmstadt, Germany

PR-M04-18-NI-82
FDA Approval

US FDA Approves TAGRISSO® (osimertinib) As 1st-Line Treatment For EGFR-Mutated Non-Small Cell Lung Cance

PR-M04-18-NI-83
Drug Development

Roche expands indication for cobas® EGFR Mutation Test v2 as a companion diagnostic with TAGRISSO®

PR-M04-18-NI-84
Innovation

Pear Therapeutics and Sandoz Announce Deal to Commercialize Prescription Digital Therapeutics

PR-M04-18-NI-81
Expanded Capacity

Avara Pharmaceutical Services Hold Groundbreaking at New Aiken Site

PR-M04-18-NI-86
FDA Approval

FDA approves first therapy for rare inherited form of rickets, x-linked hypophosphatemia

PR-M04-18-NI-80
Vaccine

Vaccibody moving forward with Cancer Neoantigen Vaccine Trial

PR-M04-18-NI-79
Clinical Development

Evotec and Bayer Advance Third Endometriosis Programme into Phase I Clinical Development

PR-M04-18-NI-78
Acquisition

JLL and Water Street Announce Acquisition to Expand Global Life Sciences Commercialization Services Platform

PR-M04-18-NI-77
Acquisition

Bruker Acquires nanoIR Company Anasys Instruments

PR-M04-18-NI-76
FDA Approval

FDA Provides Full Approval to Praxbind, Specific Reversal Agent for Pradaxa

PR-M04-18-NI-74
Awards

WuXi Biologics Wins CMO Leadership Award from Life Science Leader Magazine

PR-M04-18-NI-73
Cardiovascular

Janssen Announces Worldwide Development and Commercialization Collaboration with Bristol-Myers Squibb to Advance a Next-Generation Therapy for Cardiovascular Diseases

PR-M04-18-NI-72
Artificial Intelligence

AI-Guided Cancer Therapy Platform from SRI International Identifies Novel Molecular Targets for Aggressive Form of Breast Cancer

PR-M04-18-NI-71
Donation

Grifols Donates Over 25 million International Units of Blood Clotting Factor in 2017

PR-M04-18-NI-70
Expanded Capacity

WuXi AppTec Expands Site in the U.S. for Drug Development Testing Services

PR-M04-18-NI-75
Collaboration

Bristol-Myers Squibb and Illumina Announce Strategic Collaboration to Develop and Commercialize Companion Diagnostics

PR-M04-18-NI-64
Oncology

Opdivo (nivolumab), First PD-1 Inhibitor to Demonstrate Superior Survival Benefit Compared with Chemotherapy

PR-M04-18-NI-65